Lucence and the Diagnostics Development Hub (DxD Hub), a national platform hosted by the Agency for Science, Technology and Research (A*STAR) are collaborating to develop and pivot the use of Lucence’s multi-cancer early detection test (LucenceINSIGHT™) on alternative sample types. This collaboration represents a significant advancement in our efforts to make cancer screening more accessible to patients. We will also be partnering with local hospitals to identify and recruit eligible patients for this study. This collaborative effort aims to enhance the reach and impact of our research by leveraging the expertise and resources of our esteemed healthcare partners.
LucenceINSIGHT™ is a ctDNA-based liquid biopsy test that screens for up to 50 common cancers in one blood draw. By expanding its application to alternative sample types, such as urine, this simplifies the sample collection process, thereby lowering the cost of sample extraction. Testing of alternative sample types will make cancer screening more convenient and accessible for asymptomatic individuals.
Dr. Min-Han Tan, Lucence’s Founding CEO, emphasized, “Access to cancer screening is crucial for early detection and effective treatment. Addressing the barriers to screening empowers more individuals to proactively monitor their health before disease symptoms emerge. We are excited to advance this important initiative with DxD Hub and local hospitals to enhance population health.”
“At DxD Hub, we believe innovation goes beyond development. We collaborate closely with local companies to expand their product lines. Our ongoing work with Lucence reflects our commitment to enhancing accessibility through a non-invasive test, empowering patients to assess their disease risks while advancing precision and personalised healthcare in Singapore.” said Ms Irene Cheong, Assistant Chief Executive at A*STAR’s Innovation & Enterprise (I&E) Group.
DxD Hub and Lucence have also successfully co-developed other products with Singapore hospitals that raise the bar to provide quality care for cancer patients. One such project led to the launch of a comprehensive genomic profiling tissue test that detects clinically relevant mutations in 572 DNA genes and 71 RNA fusions to identify a patient’s unique cancer signature. Now marketed as UNITED™ 600, the comprehensive tissue panel’s results are available to the doctor within 2 weeks of ordering, to guide treatment where time is of the essence.
About Lucence
Lucence is a precision oncology company focused on bringing clarity to cancer care. Our ultrasensitive liquid biopsy tests are based on proprietary AmpliMark™ sequencing technology and data analytics for earlier detection and effective treatment. Lucence operates twin CLIA-licensed, CAP-accredited laboratories in California and Singapore. For more information, visit www.lucence.com.